(Semaglutide (Wegovy))


Drug updated on 6/1/2023

Dosage FormInjection (subcutaneous; 2.4 mg)
Drug ClassGlucagon-like peptide 1 (GLP-1) receptor agonists
Ongoing and Completed StudiesClinicalTrials.gov


  • Indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia); and in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity).

Product Monograph / Prescribing Information

Document TitleYearSource
Wegovy (semaglutide injection 2.4 mg) Prescribing Information2023Novo Nordisk, Plainsboro, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis2023BMJ Open
CADTH Reimbursement Recommendation: Semaglutide (Wegovy)2022CADTH
CADTH Reimbursement Review: Semaglutide (Wegovy)2022CADTH
Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.2022Obesity Reviews
Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs)2022Cureus
Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis2022International Journal of Clinical Pharmacy
Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review2022Therapeutic Advances in Chronic Disease
Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials2022Frontiers in Pharmacology
The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis2022Hormone and Metabolic Research
Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus—a systematic review and meta-analysis of randomized control trials2022Obesity Reviews
Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis2022Diabetes, Metabolic Syndrome and Obesity
Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review2022Clinical Epidemiology
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials2021The Lancet

Clinical Practice Guidelines